A5025334045- Influenza Virus Research Studies
- SARS-CoV-2 and COVID-19 Research
- Immunotherapy and Immune Responses
- SARS-CoV-2 detection and testing
- Monoclonal and Polyclonal Antibodies Research
- Transgenic Plants and Applications
- Viral gastroenteritis research and epidemiology
- COVID-19 Clinical Research Studies
- Biochemical and Structural Characterization
Indian Institute of Science Bangalore
2021-2023
The receptor binding domain (RBD) of SARS-CoV-2 is the primary target neutralizing antibodies. We designed a trimeric, highly thermotolerant glycan engineered RBD by fusion to heterologous, poorly immunogenic disulfide linked trimerization derived from cartilage matrix protein. protein expressed at yield ∼80-100 mg/L in transiently transfected Expi293 cells, as well CHO and HEK293 stable cell lines formed homogeneous disulfide-linked trimers. When lyophilized, these possessed remarkable...
Rapid emergence of the SARS-CoV-2 variants has dampened protective efficacy existing authorized vaccines. Nanoparticle platforms offer a means to improve vaccine immunogenicity by presenting multiple copies desired antigens in repetitive manner which closely mimics natural infection. We have applied nanoparticle display combined with SpyTag–SpyCatcher system design encapsulin–mRBD, displaying 180 monomeric spike receptor-binding domain (RBD). Here we show that encapsulin–mRBD is strongly...
Current influenza vaccines need to be updated annually due mutations in the globular head of viral surface protein, hemagglutinin (HA). To address this, vaccine candidates have been designed based on relatively conserved HA stem domain and shown protective efficacy animal models. Oligomerization antigens either by fusion oligomerization motifs or display self-assembling nanoparticle scaffolds, can induce more potent immune responses compared corresponding monomeric antigen multivalent...
Abstract Current influenza vaccines need to be updated annually due mutations in the globular head of viral surface protein, hemagglutinin (HA). To address this, vaccine candidates have been designed based on relatively conserved HA stem domain and shown protective efficacy animal models. Oligomerization antigens either by fusion oligomerization motifs or display self-assembling nanoparticle scaffolds, can induce more potent immune responses compared corresponding monomeric antigen...
Abstract The Receptor Binding Domain (RBD) of SARS-CoV-2 is the primary target neutralizing antibodies. We designed a trimeric, highly thermotolerant glycan engineered RBD by fusion to heterologous, poorly immunogenic disulfide linked trimerization domain derived from cartilage matrix protein. protein expressed at yield ∼80-100 mg/liter in transiently transfected Expi293 cells, as well CHO and HEK293 stable cell lines formed homogeneous disulfide-linked trimers. When lyophilized, these...